We fight for human health.

CureVac is the first company to successfully harness messenger RNA (mRNA) for medical purposes. The principle is promising: use natural mRNA as a data carrier to instruct the human body to produce its own proteins to fight a wide range of diseases.

  • Transition in CureVac's Top Management

    Picture: Ingmar Hoerr (left) and Dan Menichella (right)

    Read more
  • CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA

    Press Release of March 22, 2018

    Read more
  • CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria - Extends ongoing collaboration with Bill & Melinda Gates Foundation

    Press Release of February 13, 2018

    Read more
  • CureVac Highlights Key 2018 Corporate Milestones and Outlook at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco

    Press Release of January 10, 2018

    Read more
  • Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

    Press Release of October 18, 2017

    Read more
  • Work@CureVac

    Do you want to fight together with us for human health? You will find current vacancies on our CareerPortal.

    Read more